ArticleJournal of translational medicine2026
Influence of poly(styrene-co-maleic anhydride) molecular weight on nanoparticle-mediated drug delivery in breast cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPaclitaxel (PTX) is a first-line chemotherapeutic agent widely used in the treatment of multiple malignancies; however, its clinical utility is limited by poor aqueous solubility, low bioavailability, lack of tumor specificity, and systemic toxicity. Nanocarrier-based targeted delivery systems offer a promising strategy to overcome these limitations. In this study, we systematically investigated the influence of polymer molecular weight on nanoparticle performance using poly(styrene-alt-maleic anhydride) (PSMA) as a model amphiphilic polymer for breast cancer therapy.
methodsPSMA polymers with distinct molecular weights were synthesized by modulating initiator concentration, solvent system, and reaction temperature. Folic acid (FA) was covalently conjugated to surface carboxyl groups to enable tumor-targeted delivery. PTX-loaded nanoparticles were formulated from high-molecular-weight (FA-PSMAC
resultsHigh-molecular-weight FA-PSMAC
conclusionsPolymer molecular weight critically governs nanoparticle stability, biodistribution, and therapeutic efficacy. Folate-targeted high-molecular-weight PSMA nanoparticles significantly enhance PTX delivery and antitumor activity, highlighting molecular weight as a key design parameter in the rational development of targeted nanocarrier systems for breast cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.